Persistence Market Research
Bronchopulmonary dysplasia or BPD is a serious lung disease that primarily occurs in premature infants with low birth weight and to those who have needed mechanical ventilation for the treatment of respiratory distress syndrome (RDS). Bronchopulmonary dysplasia generally affects those infants who are born more than 10 weeks before their due dates coupled with breathing problems and weight less than 2 pounds at the time of their birth. Various symptoms associated with bronchopulmonary dysplasia are as follows:
Based on the diagnosis, the bronchopulmonary dysplasia market can be segmented as follows:
Based on the treatments and mediations, the bronchopulmonary dysplasia market can be segmented as follows:
Based on geography, the bronchopulmonary dysplasia market can be segmented into four major regions: North America, Europe, Asia Pacific and Rest of the World. Out of these regions, North America dominates the bronchopulmonary dysplasia market followed by Europe. The prime reasons which have contributed towards the growth of this market in these regions are high prevalence of respiratory disorders in infants and increasing genetic problems associated with lung development. According to a survey, neonatal respiratory distress syndrome which is an outcome of bronchopulmonary dysplasia in neonates is estimated to affect around 20,000-30,000 infants each year in the United States. Asia Pacific is one of the most lucrative ventures for the growth of bronchopulmonary dysplasia market as it is constantly developing at a rapid pace. The major factors which will propel the growth of this market in Asia Pacific are high birth rate, increasing awareness related to the complications of bronchopulmonary dysplasia in infants and increasing pregnancy-induced hypertension due to malnutrition. Moreover, increasing incidences of premature labor and high-risk pregnancy in mothers would drive the Asian market towards future growth.
Various pharmaceutical companies are developing novel drugs for the treatment of bronchopulmonary dysplasia. Some of the top companies operating in the market are Chiesi Farmaceutici SpA, Discovery Laboratories, Inc., Takeda Pharmaceutical Company Limited, MediPost Co., Ltd., Ikaria, Inc., Clarassance, Inc., Syntrix Biosystems, Inc. and others.
MRR.BIZ has been compiled in-depth market research data in the report after exhaustive primary and secondary research. Our team of able, experienced in-house analysts has collated the information through personal interviews and study of industry databases, journals, and reputable paid sources.
The report provides the following information:
The main aim of the report is to:
MRR.BIZ is a leading provider of strategic market research. Our vast repository consists research reports, data books, company profiles, and regional market data sheets. We regularly update the data and analysis of a wide-ranging products and services around the world. As readers, you will have access to the latest information on almost 300 industries and their sub-segments. Both large Fortune 500 companies and SMEs have found those useful. This is because we customize our offerings keeping in mind the specific requirements of our clients.